Results 151 to 160 of about 13,071 (176)

Access Barriers to Pembrolizumab in Brazil.

JAMA Netw Open
Uson Junior PLS, Rocioli UD, Teixeira MFB, Sforzin I, Andriatte G, Tustumi F, Moura F, Borad M, Moreira FT, Pedrotti CHS.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Evaluation of Adverse Events Recorded in FDA/USA and ANVISA/Brazil Databases for the Medical Equipment: Pulmonary Ventilators, Defibrillators, Infusion Pumps, Physiological Monitors and Ultrasonic Scalpels

IFMBE Proceedings, 2022
Teodiano Bastos-Filho, Sheida Mehrpour, Denis Delisle-Rodríguez   +2 more
exaly  

A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013–2016

Therapeutic Innovation and Regulatory Science, 2020
Lawrence Liberti, Neil McAuslane
exaly  

Thirteen years of medication alerts issued by the Brazilian Health Regulatory Agency (ANVISA): What is the profile?

Journal of Evaluation in Clinical Practice, 2020
André Oliveira Baldoni, Gustavo Costa Ferreira, Vitor Ferreira   +2 more
exaly  

Internal Standards (IS) Monitoring in CROs: Anvisa Perspective

Bioanalysis, 2019
Gustavo Mendes Lima Santos
exaly